Amneal Pharmaceuticals (AMRX) Asset Writedowns and Impairment (2017 - 2026)

Amneal Pharmaceuticals' Asset Writedowns and Impairment history runs 10 years deep, the most recent figure standing at $13.4 million for Q1 2026.

• In Q1 2026, Asset Writedowns and Impairment fell 43.58% year-over-year to $13.4 million; the TTM figure through Mar 2026 stood at -$389000.0 (down 100.4% YoY), while the FY2025 annual figure was $22.8 million, down 76.4% from the prior year.
• Asset Writedowns and Impairment was $13.4 million for Q1 2026 at Amneal Pharmaceuticals, up from -$36.5 million in the prior quarter.
• In the past five years, Asset Writedowns and Impairment ranged from a high of $62.7 million in Q3 2024 to a low of -$36.5 million in Q4 2025.
• Historically, Asset Writedowns and Impairment has averaged $13.2 million across 5 years, with a median of $15.7 million in 2023.
• The sharpest annual moves came in 2023 and 2024: Asset Writedowns and Impairment soared 604.42% in 2023, then sank 232.53% in 2024.
• A 5-year view of Asset Writedowns and Impairment shows it stood at $18.3 million in 2022, then slumped by 43.79% to $10.3 million in 2023, then jumped by 220.03% to $32.9 million in 2024, then tumbled by 210.91% to -$36.5 million in 2025, then surged by 136.54% to $13.4 million in 2026.
• The last three Asset Writedowns and Impairment figures came in at $13.4 million (Q1 2026), -$36.5 million (Q4 2025), and $22.8 million (Q3 2025), per Business Quant data.